Life sciences companies (particularly early stage companies) may be attracted to an LLC holding company structure as an alternative to a typical C corporation structure to maximize both the purchase price paid by a future acquiror of a drug development program and the after-tax proceeds realized by the company’s investors upon a sale.
Please see full publication below for more information.
